Global Biosimilar Markets: Comparing Europe and the United States
Explore the divergence and convergence of biosimilar markets in Europe and the US, analyzing regulatory shifts, patent battles, and cost-saving opportunities.
Tag: biosimilars
Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biosimilars in the U.S. can't enter the market until 12 years after the original biologic is approved. This delay, driven by law and patent tactics, keeps drug prices high and limits patient access - especially compared to Europe.